Grastek New FDA Drug Approval | CenterWatch

Grastek contains pollen allergen extract from Timothy grass (Phleum pratense). The precise mechanisms of action of allergen immunotherapy are not known.

Grastek is specifically indicated for use in subjects ages 5 through 65 years as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens.

For more, click the Link to article.